Lee R. Brettman, M.D., FACP
President, Chief Executive Officer and Director

Mark F. Boshar, J.D.
VP, Legal Affairs and Chief Patent Counsel

Scott Holmes, M.S., M.B.A., C.P.A.
VP, Finance and Administration

Robert C. Lorette, J.D.
Chief Business Officer and SVP

Suhail Nurbhai, MB ChB, MRCP(UK)
VP, Clinical Development

Michael W. Spellman, Ph.D.
SVP, Pharmaceutical Development

Lee R. Brettman, M.D., FACP
President, Chief Executive Officer and Director

Dr. Brettman is co-founder, president, and chief executive officer of Dynogen. Prior to Dynogen, Dr. Brettman was an entrepreneur in residence at Oxford Bioscience Partners. Prior to his tenure at Oxford, he was chief medical officer and senior vice president of medical and regulatory affairs at Millennium Pharmaceuticals. Dr. Brettman performed the same role at LeukoSite Inc. before the company merged with Millennium. Prior to joining LeukoSite, Dr. Brettman served as senior director, clinical research at Vertex Pharmaceuticals, director of anti-infectives research at the Schering Plough Research Institute and associate director of the anti-infectives group at the Robert Wood Johnson Pharmaceutical Research Institute. Throughout his career, Dr. Brettman has played a major role in the successful development leading to commercialization of a number of small molecules and biologics.

Dr. Brettman received dual bachelor’s degrees in biology and Russian literature from the Massachusetts Institute of Technology and his M.D. from the Baylor College of Medicine. He did his training in internal medicine at University Hospitals of the Case Western Reserve School of Medicine and his fellowship in infectious diseases and immunology at Bellevue Hospital and the New York University Medical School. He is board certified in internal medicine and infectious diseases and is a Fellow of the American College of Physicians and the Infectious Disease Society of America.

Mark F. Boshar, J.D.
VP of Legal Affairs and Chief Patent Counsel

Mr. Boshar is vice president of legal affairs and chief patent counsel at Dynogen. He has 20 years of experience counseling biotechnology and pharmaceutical companies in the patent and licensing areas. Mr. Boshar founded the legal department at Millennium Pharmaceuticals in 1995, and served the company as its director of legal affairs/chief patent counsel and later as its associate general counsel/chief patent counsel. Most recently, Mr. Boshar served as vice president of legal affairs for Vitivity, Inc., a subsidiary of Millennium. Prior to joining Millennium, Mr. Boshar was the chief patent counsel and director of intellectual property for Repligen Corporation. Mr. Boshar was formerly an attorney with the law firm of Hale and Dorr, LLP, (now Wilmer Cutler Pickering Hale and Dorr, LLP) where his practice focused on patent prosecution, patent litigation, and licensing matters.

Mr. Boshar received his law degree (J.D.) from Northeastern University School of Law and his bachelor’s degree in biology, magna cum laude, from Tufts University. Prior to receiving his law degree, he was a research scientist for both Genetics Institute, Inc. (now Wyeth Pharmaceuticals) and the Worcester Foundation for Experimental Biology.

Scott Holmes, M.S., M.B.A., C.P.A.
VP, Finance and Administration

Mr. Holmes is vice president of finance and administration at Dynogen. He served as Director of Finance at Dynogen from August 2005 to December 2006. Mr. Holmes joined Dynogen in October 2003 as Corporate Controller. From 2001 to 2003, Mr. Holmes was Corporate Controller at Keryx Biopharmaceuticals, Inc. a publicly-traded biopharmaceutical company. From 1997 to 2001, Mr. Holmes was with the accounting firm Ernst & Young LLP in its Mergers & Acquisitions and Audit practices. Mr. Holmes received a bachelor's degree in history from Middlebury College, and a dual Master of Science and Master of Business Administration degree from Northeastern University's Graduate School of Professional Accounting.

Robert C. Lorette, J.D.
Chief Business Officer and SVP

Mr. Lorette is chief business officer and senior vice president at Dynogen. Throughout his career, Mr. Lorette has been involved in structuring, negotiating, and closing a significant number of strategic transactions including major acquisitions, licenses, and joint ventures. Mr. Lorette was most recently senior vice president, corporate development for Boston Healthcare Associates, Inc., a firm providing management consulting and business advisory services exclusively to companies in the life science industry. Prior to joining Boston Healthcare, he was vice president of corporate development for UroMed Corporation. Before joining UroMed, Mr. Lorette held several legal and general management positions with Bausch & Lomb Incorporated, the last of which was vice president and general manager at Bausch & Lomb’s Charles River Laboratories Division. Before joining Bausch & Lomb he practiced corporate law at a private firm.

Mr. Lorette received his law degree (J.D.) from Syracuse College of Law, his M.P.A. from the Maxwell School of Syracuse University, and his bachelor’s degree in Economics from College of the Holy Cross. He attended the PMD executive development program at Harvard Business School.

Suhail Nurbhai, MB ChB, MRCP(UK)
Vice President, Clinical Development

Dr. Nurbhai is vice president for clinical development at Dynogen.  Prior to joining Dynogen, he was executive director and head of CNS clinical research and development at Pfizer, Inc. in Groton/New London Connecticut.  Prior to that, he was global clinical team leader on the overactive bladder development team and site therapeutic area leader for GI and GU development with responsibility for GI development programs and clinical input for GI licensing opportunities.  He joined Pfizer in Sandwich, England in 1993, initially working as a clinician on multinational late Phase II Programs in both irritable bowel syndrome and urinary urge incontinence.  He subsequently held positions of increasing responsibility across a number of therapeutic areas and throughout his career has been a major contributor to the development, regulatory submission and approval of compounds in the anti-bacterial, sexual dysfunction, antifungal, and GI/GU therapeutic areas.  Prior to joining Pfizer, Dr. Nurbhai practiced medicine in the gastroenterology department of Broad Green Hospital in Liverpool, England.

Dr. Nurbhai qualified in Medicine at Dundee University in Scotland.  He completed his postgraduate general medical training at the University of Manchester during which time he was elected to the Membership of the Royal College of Physicians of the United Kingdom.

Michael W. Spellman, Ph.D.
SVP, Pharmaceutical Development

Dr. Spellman is senior vice president of pharmaceutical development at Dynogen. Dr. Spellman has over 20 years of drug development experience with responsibility in areas of analytical development, preclinical development, quality assurance, quality control, and process development for a number of biotechnology companies. Prior to joining Dynogen, he was vice president of quality and then of process development at Millennium Pharmaceuticals. He also served as vice president of preclinical development at Coulter Pharmaceuticals. He was employed for nearly fourteen years at Genentech, Inc., where he led groups in analytical development and product characterization and then served as director of pharmacokinetics and metabolism. During his career in the biotechnology industry, Dr. Spellman has contributed to seven successful licensure applications, and numerous investigational new drug applications.

Dr. Spellman received a bachelor’s degree in natural science from Assumption College and a Ph.D. degree in biochemistry from Michigan State University. He did postdoctoral research in the Department of Organic Chemistry at Stockholm University in Sweden.